capmatinib
Trade name: Tabrecta
Small moleculeapprovedOrphan Drug FDABreakthrough Therapy FDA
Approved
May 6, 2020
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. — Wikipedia
Clinical trial activity
49 trials · 30 clinical orgs · 1 marketing orgs
Phase 1
18
Phase 2
33
Phase 3
4
Phase 4
2
Earliest trial started Jan 1, 2010 (NCT01072266)
Timeline
2010s
Indications
Approved for
Studied for
- Biomarkers · Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 4
- Carcinoma, Renal Cell · Phase 1
- Colorectal Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 2
- Glioblastoma · Phase 1/Phase 2
- Glioma · Phase 2/Phase 3
- Gliosarcoma · Phase 1
- Kidney Neoplasms · Phase 2
- Liver Diseases · Phase 1
- Lung Neoplasms · Phase 2
- Melanoma · Phase 2
- Mutation · Phase 2
- Neoplasms · Phase 4
- Neoplasms by Histologic Type · Phase 2/Phase 3
- Neoplasms by Site · Phase 2/Phase 3
- Neuroblastoma · Phase 2/Phase 3
- Oncogene Proteins · Phase 2
- Oncogenes · Phase 2
- Proto-Oncogene Proteins B-raf · Phase 2
- Proto-Oncogene Proteins c-met · Phase 2
- ras Proteins · Phase 2
- Sarcoma · Phase 3
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Stomach Neoplasms · Phase 2/Phase 3
Mechanism of action
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Approval history
- approvedPriority reviewAcceleratedBreakthroughMay 6, 2020
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F- Mol. weight
- 412.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaIncyte ↗
- ChEMBLCHEMBL3989937 ↗
- ChEMBLCHEMBL3188267 ↗
Also known as
- capmatinib
- capmatinib
- capmatinib
- capmatinib
- capmatinib
- inc280
- inc280
- inc280
- inc-280
- inc-280
- incb028060
- incb-28060
- incb-28060
- nvp-inc280
- nvp-inc280
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06988475 | Phase 2/Phase 3 (Phase 3) | Nov 19, 2024 | Cancer Research UK, Novartis, Royal Marsden Hospital NHS Trust, The Christie NHS Foundation Trust, University of Birmingham, University of Manchester |
| NCT06054191 | Phase 2 | Feb 1, 2024 | Sun Yat-Sen University |
| NCT05642572 | Phase 2 | Apr 22, 2023 | National Cancer Institute (NCI), Southwest Oncology Group |
| NCT05567055 | Phase 2 | Dec 31, 2022 | Novartis, University of Pittsburgh |
| NCT05488314 | Phase 2 | Nov 28, 2022 | — |
| NCT05243641 | Phase 1/Phase 2 (Phase 2) | Aug 18, 2022 | Celcuity, Novartis, Puma Biotechnology, Inc., University of Texas at Houston |
| NCT05435846 | Phase 1 | Aug 10, 2022 | Novartis, University of California, San Francisco |
| NCT04926831 | Phase 2 | Dec 30, 2021 | Novartis |
| NCT05110196 | Phase 4 | Dec 1, 2021 | Novartis |
| NCT05135845 | Phase 2 | Nov 30, 2021 | Assistance Publique - Hôpitaux de Paris |
| NCT04816214 | Phase 3 | Sep 22, 2021 | Novartis |
| NCT04677595 | Phase 2 | Apr 29, 2021 | Novartis |
| NCT04460729 | Phase 2 | Nov 11, 2020 | Novartis |
| NCT04427072 | Phase 3 | Aug 27, 2020 | Novartis |
| NCT04323436 | Phase 2 | Jun 15, 2020 | Novartis |
| NCT04139317 | Phase 2 | Jan 16, 2020 | Novartis |
| NCT03784014 | Phase 3 | Mar 31, 2019 | Commissariat A L'energie Atomique, Hôpital Européen Georges-Pompidou, Institut Bergonié, Institut National de la Santé Et de la Recherche Médicale, France |
| NCT03742349 | Phase 1 | Jan 31, 2019 | Novartis |
| NCT03647488 | Phase 2 | Nov 19, 2018 | Novartis |
| NCT03693339 | Phase 2 | Oct 30, 2018 | University of Ulsan |
Showing 20 of 49 trials
Page 1 / 3
Organizations
Research & Development (30)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 40 | 32 | 5 | 2010 |
| National Cancer Institute (NCI) | Government | 3 | 1 | 2 | 2013 |
| University of California, San Francisco | Academic/Hospital | 2 | 2 | 2 | 2016 |
| Array BioPharma | For profit | 1 | 1 | 1 | 2014 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Celcuity | For profit | 1 | 0 | 1 | 2022 |
| Commissariat A L'energie Atomique | Government | 1 | 0 | 1 | 2019 |
| Davita Clinical Research | For profit | 1 | 0 | 1 | 2015 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2016 |
| Hôpital Européen Georges-Pompidou | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Incyte | For profit | 1 | 1 | 1 | 2010 |
| Institut Bergonié | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Orlando Clinical Research Center | For profit | 1 | 0 | 1 | 2015 |
| Puma Biotechnology, Inc. | For profit | 1 | 0 | 1 | 2022 |
| Royal Marsden Hospital NHS Trust | Academic/Hospital | 1 | 0 | 1 | 2024 |
| SCRI Development Innovations | For profit | 1 | 1 | 1 | 2015 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2023 |
30 organizations
Page 1 / 2